
WE CLAIM:

1. A compound having the following formula IJ



IJ

a is a bond;

$U^5$ is C;

$R^a$, $R^b$ are each independently H or halo or alkyl;

$R^2$ is

(i) phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or pyridinyl, any of which may be optionally independently substituted with one or more $R^{10}$ as allowed by valence,

$R^{2a}$ and $R^{2b}$ are independently selected at each occurrence from H or halo

$R^4$ is independently selected at each occurrence from H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, and cycloalkylalkyl, any of which may be optionally independently substituted as allowed by valence with one or more $R^{10}$ groups;

$R^5$ and $R^{5a}$ are independently selected at each occurrence from H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, and cycloalkylalkyl, any of which may be optionally substituted as allowed by valence with one or more $R^{10}$;

$R^{10}$ at each occurrence is independently, halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, -(alkylene)$_m$-$OR^4$, -(alkylene)$_m$-$S(O)_vR^4$, -(alkylene)$_m$-$NR^5R^{5a}$, -(alkylene)$_m$-$C(=O)R^4$, -(alkylene)$_m$-$C(=S)R^4$, -(alkylene)$_m$-$C(=O)OR^4$, -(alkylene)$_m$-$OC(=O)R^4$, -(alkylene)$_m$-$C(=S)OR^4$, -(alkylene)$_m$-$C(=O)NR^5R^{5a}$, -(alkylene)$_m$-$C(=S)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=S)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)R^4$, -(alkylene)$_m$-$N(R^5)C(=S)R^4$, -(alkylene)$_m$-$OC(=O)NR^5R^{5a}$, -(alkylene)$_m$-$OC(=S)NR^5R^{5a}$, -(alkylene)$_m$-$SO_2NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)SO_2R^4$, -(alkylene)$_m$-$N(R^5)SO_2NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)OR^4$, -(alkylene)$_m$-$N(R^5)C(=S)OR^4$, or -(alkylene)$_m$-$N(R^5)SO_2R^4$;

$R^{10d}$ at each occurrence is independently –OMe, –OEt-OMe, -$OMeCF_3$, pyrazolylmethyl or isoxazolylmethyl;

wherein said alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl groups may be further independently substituted with one or more -(alkylene)$_m$-$OR^4$, -(alkylene)$_m$-$S(O)_vR^4$, -(alkylene)$_m$-$NR^5R^{5a}$, -(alkylene)$_m$-$C(=O)R^4$, -(alkylene)$_m$-$C(=S)R^4$, -(alkylene)$_m$-$C(=O)OR^4$, -(alkylene)$_m$-$OC(=O)R^4$, -(alkylene)$_m$-$C(=S)OR^4$, —(alkylene)$_m$-$C(=O)NR^5R^{5a}$, -(alkylene)$_m$-$C(=S)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=S)NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)R^4$, -(alkylene)$_m$-$N(R^5)C(=S)R^4$, -(alkylene)$_m$-$OC(=O)NR^5R^{5a}$, -(alkylene)$_m$-$OC(=S)NR^5R^{5a}$, -(alkylene)$_m$-$SO_2NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)SO_2R^4$, -(alkylene)$_m$-$N(R^5)SO_2NR^5R^{5a}$, -(alkylene)$_m$-$N(R^5)C(=O)OR^4$, -(alkylene)$_m$-$N(R^5)C(=S)OR^4$, or -(alkylene)$_m$-$N(R^5)SO_2R^4$;

m is 0 or 1;

n is 0;

n+ is 0, 1, 2 or 3;







q is 0;













v is 0, 1 or 2; or salts thereof

2. A compound of claim 1 wherein $R^2$ is phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, tetrahydropyridinyl, pyridinonyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, indolinonyl, isoidolinyl, isoindolinonyl, dihydrobenzofuranyl,

dihydroisobenzofuranyl, benzofuranyl, isobenzofuranyl, quinolinyl, isoquinolinyl, quinazolinyl, quinazolinonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, quinoxalinyl, tetrahydroquinoxalinyl, benzomorpholinyl, dihydrobenzodioxinyl, imidazopyridinyl, naphthyridinyl, benzotriazinyl, triazolopyridinyl, triazolopyrimidinyl, triazolopyridazinyl, imidazopyridinyl, imidazopyrimidinyl, imidazopyridazinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, cinnolinyl, thienopyrrolyl, tetrahydrothienopyrrolyl, dihydrothienopyrrolonyl, thienopyridinyl, thienopyrimidinyl, thienopyridazinyl, furopyridinyl, furopyrimidinyl, furopyrazidinyl, benzofuranyl, benzoimidazolyl, benzoisoxazolyl, benzothiazolyl, or benzoisothiazolyl any of which may be optionally independently substituted with one or more $R^{10}$ groups as allowed by valence; or salts thereof.

3. A compound selected from:


,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

and

,

and salts thereof.

4. A pharmaceutical composition comprising a compound of claim 1 or salts thereof together with a pharmaceutically acceptable vehicle or carrier.

5. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for treating cancer in a subject.


6. The use of claim 5, wherein the medicament is used in combination with at least one compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.

7. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing tumor size in a subject.


8. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for treating HGF mediated disorders in a subject.

9. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing metastasis in a tumor in a subject.


10. A compound, or a pharmaceutically acceptable salt thereof according to claim 1, that is




11. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




12. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




13. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




14. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




15. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




16. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




17. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




18. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




19. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




20. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




21. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




22. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




23. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




24. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




25. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




26. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




27. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




28. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




29. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




30. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




31. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




32. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




33. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




34. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




35. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




36. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




37. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




38. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




39. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is



40. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is




41. A compound or a pharmaceutically acceptable salt thereof according to claim 1, that is



WE CLAIM:

1. A compound having the following formula IJ



IJ

a is a bond or is absent;

$U^5$ is C or N;

Z is -O-, $-S(O)_v$-, or $-NR^5$-;

$R^a$, $R^b$, $R^c$ and $R^d$ are each independently H, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, $-NO_2$, -CN, $-NR^5R^{5a}$, $-OR^4$, $-C(=O)R^4$, $-C(=O)OR^4$; $-C(=O)NR^5R^{5a}$, $-N(R^5)C(=O)NR^5R^{5a}$, $-OC(=O)NR^5R^{5a}$, $-S(O)_vR^4$, $-S(O)_2NR^5R^{5a}$, $-N(R^5)SO_2R^4$ any of which may be optionally independently substituted with one or more $R^{10}$ groups as allowed by valence;

$R^2$ is

(i) cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, any of which may be optionally independently substituted with one or more $R^{10}$ as allowed by valence,

$R^{2a}$ and $R^{2b}$ are independently selected at each occurrence from H, halo, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, $R^4$ is independently selected at each occurrence from H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, and

cycloalkylalkyl, any of which may be optionally independently substituted as allowed by valence with one or more $R^{10}$ groups;

$R^5$ and $R^{5a}$ are independently selected at each occurrence from H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, and cycloalkylalkyl, any of which may be optionally substituted as allowed by valence with one or more $R^{10}$;

$R^{10}$ and $R^{10d}$ at each occurrence is independently, halo, cyano, nitro, oxo, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkyl, $-(alkylene)_m-OR^4$, $-(alkylene)_m-S(O)_vR^4$, $-(alkylene)_m-NR^5R^{5a}$, $-(alkylene)_m-C(=O)R^4$, $-(alkylene)_m-C(=S)R^4$, $-(alkylene)_m-C(=O)OR^4$, $-(alkylene)_m-OC(=O)R^4$, $-(alkylene)_m-C(=S)OR^4$, $-(alkylene)_m-C(=O)NR^5R^{5a}$, $-(alkylene)_m-C(=S)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=S)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)R^4$, $-(alkylene)_m-N(R^5)C(=S)R^4$, $-(alkylene)_m-OC(=O)NR^5R^{5a}$, $-(alkylene)_m-OC(=S)NR^5R^{5a}$, $-(alkylene)_m-SO_2NR^5R^{5a}$, $-(alkylene)_m-N(R^5)SO_2R^4$, $-(alkylene)_m-N(R^5)SO_2NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)OR^4$, $-(alkylene)_m-N(R^5)C(=S)OR^4$, or $-(alkylene)_m-N(R^5)SO_2R^4$;

wherein said alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkyl groups may be further independently substituted with one or more $-(alkylene)_m-OR^4$, $-(alkylene)_m-S(O)_vR^4$, $-(alkylene)_m-NR^5R^{5a}$, $-(alkylene)_m-C(=O)R^4$, $-(alkylene)_m-C(=S)R^4$, $-(alkylene)_m-C(=O)OR^4$, $-(alkylene)_m-OC(=O)R^4$, $-(alkylene)_m-C(=S)OR^4$, $-(alkylene)_m-C(=O)NR^5R^{5a}$, $-(alkylene)_m-C(=S)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=S)NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)R^4$, $-(alkylene)_m-N(R^5)C(=S)R^4$, $-(alkylene)_m-OC(=O)NR^5R^{5a}$, $-(alkylene)_m-OC(=S)NR^5R^{5a}$, $-(alkylene)_m-SO_2NR^5R^{5a}$, $-(alkylene)_m-N(R^5)SO_2R^4$, $-(alkylene)_m-N(R^5)SO_2NR^5R^{5a}$, $-(alkylene)_m-N(R^5)C(=O)OR^4$, $-(alkylene)_m-N(R^5)C(=S)OR^4$, or $-(alkylene)_m-N(R^5)SO_2R^4$;

m is 0 or 1;

n is 0, 1 or 2;

n+ is 0, 1, 2 or 3;

q is 0 or 1;

v is 0, 1 or 2; or salts thereof

2. A compound of claim 1 wherein q and n are each zero, and a is a bond; or salts thereof.

3. A compound of claim 1 wherein $R^2$ is phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, tetrahydropyridinyl, pyridinonyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, indolinonyl, isoidolinyl, isoindolinonyl, dihydrobenzofuranyl, dihydroisobenzofuranyl, benzofuranyl, isobenzofuranyl, quinolinyl, isoquinolinyl, quinazolinyl, quinazolinonyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, quinoxalinyl, tetrahydroquinoxalinyl, benzomorpholinyl, dihydrobenzodioxinyl, imidazopyridinyl, naphthyridinyl, benzotriazinyl, triazolopyridinyl, triazolopyrimidinyl, triazolopyridazinyl, imidazopyridinyl, imidazopyrimidinyl, imidazopyridazinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, cinnolinyl, thienopyrrolyl, tetrahydrothienopyrrolyl, dihydrothienopyrrolonyl, thienopyridinyl, thienopyrimidinyl, thienopyridazinyl, furopyridinyl, furopyrimidinyl, furopyrazidinyl, benzofuranyl, benzoimidazolyl, benzoisoxazolyl, benzothiazolyl, or benzoisothiazolyl any of which may be optionally independently substituted with one or more $R^{10}$ groups as allowed by valence; or salts thereof.

4. A compound of claim 3, wherein $U^5$ is C, or salts thereof.













5. A compound of claim 4, wherein $R^{2a}$ and $R^{2b}$ are H or halo, or salts thereof.
















6. A compound of claim 4, wherein $R^a$ and $R^b$ are each independently H, halo or alkyl, or salts thereof.






7. A compound of claim 3, wherein $R^2$ is phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl or pyridinyl, any of which may be optionally independently substituted with one or more $R^{10}$ groups as allowed by valence; or salts thereof.

8. A compound of claim 7, wherein $R^{10d}$ is –OMe, –OEt-OMe, -$OMeCF_3$, pyrazolylmethyl, isoxazolylmethyl, or salts thereof.

9. A compound selected from:


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

and

,

and salts thereof.

10. A pharmaceutical composition comprising a compound of claim 1 or salts thereof together with a pharmaceutically acceptable vehicle or carrier.

11. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for treating cancer in a subject.


12. The use of claim 9, wherein the medicament is used in combination with at least one compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.

13. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing tumor size in a subject.


14. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for treating HGF mediated disorders in a subject.

15. Use of a compound of claim 1 or salts thereof in the manufacture of a medicament for reducing metastasis in a tumor in a subject.


16. A compound, or a pharmaceutically acceptable salt thereof, that is


.


17. A compound or a pharmaceutically acceptable salt thereof, that is




18. A compound or a pharmaceutically acceptable salt thereof, that is




19. A compound or a pharmaceutically acceptable salt thereof, that is




20. A compound or a pharmaceutically acceptable salt thereof, that is




21. A compound or a pharmaceutically acceptable salt thereof, that is




22. A compound or a pharmaceutically acceptable salt thereof, that is




23. A compound or a pharmaceutically acceptable salt thereof, that is




24. A compound or a pharmaceutically acceptable salt thereof, that is




25. A compound or a pharmaceutically acceptable salt thereof, that is




26. A compound or a pharmaceutically acceptable salt thereof, that is




27. A compound or a pharmaceutically acceptable salt thereof, that is




28. A compound or a pharmaceutically acceptable salt thereof, that is




29. A compound or a pharmaceutically acceptable salt thereof, that is




30. A compound or a pharmaceutically acceptable salt thereof, that is




31. A compound or a pharmaceutically acceptable salt thereof, that is




32. A compound or a pharmaceutically acceptable salt thereof, that is




33. A compound or a pharmaceutically acceptable salt thereof, that is




34. A compound or a pharmaceutically acceptable salt thereof, that is




35. A compound or a pharmaceutically acceptable salt thereof, that is




36. A compound or a pharmaceutically acceptable salt thereof, that is




37. A compound or a pharmaceutically acceptable salt thereof, that is




38. A compound or a pharmaceutically acceptable salt thereof, that is




39. A compound or a pharmaceutically acceptable salt thereof, that is




40. A compound or a pharmaceutically acceptable salt thereof, that is




41. A compound or a pharmaceutically acceptable salt thereof, that is




42. A compound or a pharmaceutically acceptable salt thereof, that is




43. A compound or a pharmaceutically acceptable salt thereof, that is




44. A compound or a pharmaceutically acceptable salt thereof, that is



45. A compound or a pharmaceutically acceptable salt thereof, that is



46. A compound or a pharmaceutically acceptable salt thereof, that is



47. A compound or a pharmaceutically acceptable salt thereof, that is

